TrialNature communications2024

Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma.

Olivia Le Saux et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.